NCT04840758UNKNOWNanonymous

A Prospective Single-arm Single-center Clinical Study：Assessment of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer (sMPLC)

Sponsor

Source record

The First Affiliated Hospital of Xiamen University

Phase

Source record

PHASE1

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Stereotactic Ablation Radiotherapy, Sintilimab

Indication / condition

AI-normalized

Multiple Primary Lung Cancer

Intervention

Source record

Stereotactic Ablation Radiotherapy, Sintilimab

Source & freshness

Source record

NCT ID

NCT04840758

Original source

ClinicalTrials.gov

Source last updated

Apr 12, 2021

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04840758

Title

A Prospective Single-arm Single-center Clinical Study：Assessment of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer (sMPLC)

Sponsor

The First Affiliated Hospital of Xiamen University

Status

UNKNOWN

Phase

PHASE1

Condition raw

Multiple Primary Lung Cancer

Condition normalized

Multiple Primary Lung Cancer

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Stereotactic Ablation Radiotherapy, Sintilimab

Target normalized

Stereotactic Ablation Radiotherapy, Sintilimab

Interventions

Stereotactic Ablation Radiotherapy, Sintilimab

Public preview

Source record

The purpose of this study is to assess of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) combined with Sintilimab in early inoperable synchronous Multiple Primary Lung Cancer (sMPLC)

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Prospective Single-arm Single-center Clinical Study：Assessment of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer (sMPLC)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04840758

Status

UNKNOWN

Phase

PHASE1

Sponsor

The First Affiliated Hospital of Xiamen University

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 12, 2021

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04840758

Indication

Multiple Primary Lung Cancer

Modality

monoclonal antibody

Target

Stereotactic Ablation Radiotherapy, Sintilimab

Intervention

Stereotactic Ablation Radiotherapy, Sintilimab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.